Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.35 |
| ▸ | ITGB1 | P05556 | 11/20 | 0.34 |
| ▸ | ITGA4 | P13612 | 10/20 | 0.34 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
| ▸ | ITGAL | P20701 | 1/20 | 0.33 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.33 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.33 |
| ▸ | ITGAV | P06756 | 2/20 | 0.33 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.33 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29736403 | 1.00 | NLRP3 (0.35) | NLRP3ITGB1ITGA4ITGB2ICAM1 | |
| SCHEMBL22017152 | 1.00 | NLRP3 (0.35) | NLRP3ITGB1ITGA4ITGB2ICAM1 | |
| SCHEMBL21954980 | 0.92 | ITGB1 (0.41) | ITGB1ITGA4ITGB2ICAM1ITGAL | |
| SCHEMBL21954979 | 0.92 | ITGB1 (0.41) | ITGB1ITGA4ITGB2ICAM1ITGAL | |
| SCHEMBL29736579 | 0.90 | NLRP3 (0.35) | NLRP3ITGA4ITGB2ICAM1ITGAL | |
| SCHEMBL22017367 | 0.90 | NLRP3 (0.35) | NLRP3ITGA4ITGB2ICAM1ITGAL | |
| SCHEMBL22016803 | 0.85 | ITGB1 (0.35) | ITGB1ITGA4ITGB2ICAM1ITGAL | |
| SCHEMBL21954964 | 0.82 | ITGB2 (0.42) | ITGB1ITGA4ITGB2ICAM1ITGAL | |
| SCHEMBL21954965 | 0.82 | ITGB2 (0.42) | ITGB1ITGA4ITGB2ICAM1ITGAL | |
| SCHEMBL22031418 | 0.81 | ITGB2 (0.42) | ITGB1ITGA4ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | GILEAD SCIENCES, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155563-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | NLRP3 3315/4885ITGB1 4/4885ITGA4 3/4885 |
| US-11224600-B2 | Compounds for inhibition of alpha 4 beta 7 integrin | ITGB7, ITGB4, ITGA4 | NLRP3 3315/4885ITGB1 4/4885ITGA4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.